Abbott ABT Pharmaceuticals — Remaining performance obligations
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Abbott in its filing.
Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.
The source filing: Abbott’s 10-Q, filed July 28, 2026.
- Filed
- Jul 28, 2026, 4:02 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050134
As of June 30, 2026, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was $6.2 billion in the Diagnostic Products segment, $455 million in the Medical Devices segment, and $243 million in the Established Pharmaceuticals Products segment. Abbott expects to recognize revenue on approximately 52 percent of these remaining performance obligations over the next 24 months, approximately 18 percent over the subsequent 12 months, and the remainder thereafter.
Item 1. Financial Statements and Supplementary Data
FAQ
- What is Abbott's pharmaceuticals — remaining performance obligations?
- Abbott (ABT) reported pharmaceuticals — remaining performance obligations of $243M in Q2 2026.
- What does pharmaceuticals — remaining performance obligations mean?
- This metric represents the total transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting period for the pharmaceuticals segment. It reflects the value of contracted revenue that the company expects to recognize in future periods as it fulfills its obligations under existing agreements. This provides visibility into the long-term revenue pipeline and the stability of future cash flows within the branded generics business.
Ask your AI about Abbott's pharmaceuticals — remaining performance obligations.
Connect your AI assistant and compare segments, right in your chat.
